Treatment and diagnosis of severe KPC-producing Klebsiella pneumoniae infections: a perspective on what has changed over last decades

References

• Shallcross LJ, Howard SJ, Fowler T, et al. Tackling the threat of antimicrobial resistance: from policy to sustainable action. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140082.
   PubMed Web of Science ®Google Scholar
• Gupta N, Limbago BM, Patel JB, et al. Carbapenem-resistant enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53(1):60–67.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Mikulska M, Viscoli C. Recent advances in the pharmacological management of infections due to multidrug-resistant gram-negative bacteria. Expert Rev Clin Pharmacol. 2018;11(12):1219–1236.
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785–796.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682–707.
   PubMed Web of Science ®Google Scholar
• Bush K, Bradford PA. Epidemiology of beta-lactamase-producing pathogens. Clin Microbiol Rev. 2020;33(2):e00047-19
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Galani I, Papoutsaki V, et al. Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies. Expert Rev Anti Infect Ther. 2022;20(1):53–69.
   PubMed Web of Science ®Google Scholar
• Yahav D, Giske CG, Grāmatniece A, et al. New beta-lactam-beta-lactamase inhibitor combinations. Clin Microbiol Rev. 2020;34(1):e00115-20.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Giamarellou H, et al. Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect. 2018;24(2):133–144.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–950.
   PubMed Web of Science ®Google Scholar
• Papagiannitsis CC, Di Pilato V, Giani T, et al. Characterization of KPC-encoding plasmids from two endemic settings, Greece and Italy. J Antimicrob Chemother. 2016;71(10):2824–2830.
   PubMed Web of Science ®Google Scholar
• Chen L, Mathema B, Chavda KD, et al. Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding. Trends Microbiol. 2014;22(12):686–696.
   PubMed Web of Science ®Google Scholar
• Li Z, Velkov T. Polymyxins: mode of action. Adv Exp Med Biol. 2019;1145:37–54.
   PubMed Web of Science ®Google Scholar
• Maraolo AE, Corcione S, Grossi A, et al. The impact of carbapenem resistance on mortality in patients With Klebsiella Pneumoniae bloodstream infection: an individual patient data meta-analysis of 1952 patients. Infect Dis Ther. 2021;10(1):541–558.
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), european society of clinical microbiology and infectious diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-Infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39.
   PubMed Web of Science ®Google Scholar
• Nation RL, Forrest A. Clinical pharmacokinetics, pharmacodynamics and toxicodynamics of polymyxins: implications for therapeutic use. Adv Exp Med Biol. 2019;1145:219–249.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Karaiskos I, Bassetti M. How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients? Expert Opin Pharmacother. 2022;23(1):5–8.
   PubMed Web of Science ®Google Scholar
• Matuschek E, Ahman J, Webster C, et al. Antimicrobial susceptibility testing of colistin – evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. Clin Microbiol Infect. 2018;24(8):865–870.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–2328.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Rosa D, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133–2143.
   PubMed Web of Science ®Google Scholar
• Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-Treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018;67(12):1803–1814.
   PubMed Web of Science ®Google Scholar
• Antonello RM, Di Bella S, Maraolo AE, et al. Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies. Eur J Clin Microbiol Infect Dis. 2021;40(6):1117–1126.
   PubMed Web of Science ®Google Scholar
• Cojutti P, Sartor A, Righi E, et al. Population pharmacokinetics of high-dose continuous-infusion meropenem and considerations for use in the treatment of infections due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61(10):e00794-17.
   PubMed Web of Science ®Google Scholar
• Del Bono V, Giacobbe DR, Marchese A, et al. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: should we get to the PK/PD root of the paradox? Virulence. 2017;8(1):66–73.
   PubMed Web of Science ®Google Scholar
• Duong A, Simard C, Wang YL, et al. Aminoglycosides in the intensive care unit: what Is new in population PK modeling? Antibiotics. 2021;10(5):507.
   Google Scholar
• Giacobbe DR, Bono D, Trecarichi V, et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect. 2015;21(12):1106–1108.
   Web of Science ®Google Scholar
• Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol. 2011;7(11):1459–1470.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Friberg LE, Pontikis K, et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients. Antimicrob Agents Chemother. 2015;59(12):7240–7248.
   PubMed Web of Science ®Google Scholar
• Monaco M, Giani T, Raffone M, et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy. Euro Surveill. 2014;19(42):20939.
   PubMedGoogle Scholar
• Nation RL, Garonzik SM, Li J, et al. Updated US and european dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis. 2016;62(5):552–558.
   PubMed Web of Science ®Google Scholar
• Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant enterobacteriaceae infections: a systematic review and meta-analysis. Medicine. 2016;95(11):e3126.
   PubMed Web of Science ®Google Scholar
• Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest. 2005;128(2):545–552.
   PubMed Web of Science ®Google Scholar
• Wang G, Yu W, Cui Y, et al. Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using monte carlo simulation. BMC Infect Dis. 2021;21(1):307.
   PubMed Web of Science ®Google Scholar
• Zha L, Pan L, Guo J, et al. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis. Adv Ther. 2020;37(3):1049–1064.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Gutierrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–734.
   PubMed Web of Science ®Google Scholar
• Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect. 2021.
   Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious diseases society of america 2022 guidance on the treatment of extended-spectrum beta-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75(2):187–212.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–240.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439–455.
   PubMed Web of Science ®Google Scholar
• de Kraker MEA, Sommer H, de Velde F, et al. Optimizing the design and analysis of clinical trials for antibacterials against multidrug-resistant organisms: a white paper from COMBACTE's STAT-Net. Clin Infect Dis. 2018;67(12):1922–1931.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355–364.
   PubMed Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171.
   PubMed Web of Science ®Google Scholar
• Kang Y, Zhou Q, Cui J. Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in Northern China. J Glob Antimicrob Resist. 2021;27:67–71.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Daikos GL, Gkoufa A, et al. Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study. J Antimicrob Chemother. 2021;76(3):775–783.
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant enterobacteriaceae infections. Antimicrob Agents Chemother. 2018;62(5):e02497–17.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Raffaelli F, Giannella M, et al. Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study. Clin Infect Dis. 2021;73(9):1664–1676.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Bassetti M. Innovative beta-lactam/beta-lactamase inhibitor combinations for carbapenem-resistant gram-negative bacteria. Future Microbiol. 2022;17:393–396.
   PubMed Web of Science ®Google Scholar
• Lawandi A, Yek C, Kadri SS. IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR gram-negative infections. Clin Microbiol Infect. 2022;28(4):465–469.
   PubMed Web of Science ®Google Scholar
• Xu M, Zhao, J, Xu L, et al. Emergence of transferable ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae due to a novel CMY AmpC beta-lactamase in China. Clin Microbiol Infect. 2022;28(1)e1-136–e6.136.
   Web of Science ®Google Scholar
• Venditti C, Butera O, Meledandri M, et al. Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae. Clin Microbiol Infect. 2021;27(7)e6.1040:e1-1040.
   Web of Science ®Google Scholar
• Nelson K, Hemarajata P, Sun D, et al. Resistance to ceftazidime-avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity. Antimicrob Agents Chemother. 2017;61(10):e00989–17.
   PubMed Web of Science ®Google Scholar
• Di Bella S, Giacobbe DR, Maraolo AE, et al. Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing enterobacterales: a systematic review of observational clinical studies. J Glob Antimicrob Resist. 2021;25:268–281.
   PubMed Web of Science ®Google Scholar
• Gaibani P, Giani T, Bovo F, et al. Resistance to ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam in gram-negative MDR bacilli: molecular mechanisms and susceptibility testing. Antibiotics. 2022;11(5):628.
   Google Scholar
• Jorgensen SCJ, Rybak MJ. Meropenem and vaborbactam: stepping up the battle against carbapenem-resistant enterobacteriaceae. Pharmacotherapy. 2018;38(4):444–461.
   PubMed Web of Science ®Google Scholar
• Dulyayangkul P, Douglas EJA, Lastovka F, et al. Resistance to ceftazidime/avibactam plus meropenem/vaborbactam when both are used together is achieved in four steps in metallo-beta-lactamase-negative Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(10):e00409–20.
   PubMed Web of Science ®Google Scholar
• Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of imipenem with relebactam against gram-negative pathogens from New York city. Antimicrob Agents Chemother. 2015;59(8):5029–5031.
   PubMed Web of Science ®Google Scholar
• Balabanian G, Rose M, Manning N, et al. Effect of porins and blaKPC expression on activity of imipenem with relebactam in Klebsiella pneumoniae: can antibiotic combinations overcome resistance? Microb Drug Resist. 2018;24(7):877–881.
   PubMed Web of Science ®Google Scholar
• Di Pilato V, Principe L, Andriani L, et al. Deciphering variable resistance to novel carbapenem-based β-lactamase-inhibitor combinations in a multiclonal outbreak by KPC carbapenemase-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam. Clin Microbiol Infect. 2022. doi: 10.1016/j.cmi.2022.11.011
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible gram-negative bacilli, including serine carbapenemase- and metallo-beta-lactamase-producing isolates (SIDERO-WT-2014 study). Int J Antimicrob Agents. 2019;53(2):177–184.
   PubMed Web of Science ®Google Scholar
• Hobson CA, Cointe A, Jacquier H, et al. Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC beta-lactamase mutants and the inoculum effect. Clin Microbiol Infect. 2021;27(8):1172:e7–1172:e10.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep. 2009;58(10):256–260.
   PubMedGoogle Scholar
• EUCAST. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Available from: https://eucast.org/. 2017.
   Google Scholar
• Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9(4):228–236.
   PubMed Web of Science ®Google Scholar
• Lutgring JD, Limbago BM. The problem of carbapenemase-producing-carbapenem-resistant-enterobacteriaceae detection. J Clin Microbiol. 2016;54(3):529–534.
   PubMed Web of Science ®Google Scholar
• Pournaras S, Poulou A, Tsakris A. Inhibitor-based methods for the detection of KPC carbapenemase-producing enterobacteriaceae in clinical practice by using boronic acid compounds. J Antimicrob Chemother. 2010;65(7):1319–1321.
   PubMed Web of Science ®Google Scholar
• Dortet L, Poirel L, Nordmann P. Rapid identification of carbapenemase types in enterobacteriaceae and Pseudomonas spp. by using a biochemical test. Antimicrob Agents Chemother. 2012;56(12):6437–6440.
   PubMed Web of Science ®Google Scholar
• Girlich D, Halimi D, Zambardi G, et al. Evaluation of etest(R) strips for detection of KPC and metallo-carbapenemases in enterobacteriaceae. Diagn Microbiol Infect Dis. 2013;77(3):200–201.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Simner PJ. Phenotypic detection of carbapenemase-producing organisms from clinical isolates. J Clin Microbiol. 2018;56(11):e01140-18.
   PubMed Web of Science ®Google Scholar
• Hrabak J, Chudackova E, Papagiannitsis CC. Detection of carbapenemases in enterobacteriaceae: a challenge for diagnostic microbiological laboratories. Clin Microbiol Infect. 2014;20(9):839–853.
   PubMed Web of Science ®Google Scholar
• Hleba L, Hlebova M, Kovacik A, et al. Carbapenemase producing Klebsiella pneumoniae (KPC): what is the best MALDI-TOF MS detection method. Antibiotics. 2021;10(12):1549.
   Google Scholar
• Vasilakopoulou A, Karakosta P, Vourli S, et al. Detection of KPC, NDM and VIM-producing organisms directly from rectal swabs by a multiplex lateral flow immunoassay. Microorganisms. 2021;9(5):942.
   PubMed Web of Science ®Google Scholar
• Buchan BW, Ledeboer NA. Emerging technologies for the clinical microbiology laboratory. Clin Microbiol Rev. 2014;27(4):783–822.
   PubMed Web of Science ®Google Scholar
• Rentschler S, Kaiser L, Deigner HP. Emerging options for the diagnosis of bacterial infections and the characterization of antimicrobial resistance. Int J Mol Sci. 2021;22(1):456.
   PubMed Web of Science ®Google Scholar
• Dumkow LE, Worden LJ, Rao SN. Syndromic diagnostic testing: a new way to approach patient care in the treatment of infectious diseases. J Antimicrob Chemother. 2021;76(Suppl 3):iii4–iii11.
   PubMedGoogle Scholar
• Ramanan P, Bryson AL, Binnicker MJ, et al. Syndromic panel-based testing in clinical microbiology. Clin Microbiol Rev. 2018;31(1):e00024-17.
   PubMed Web of Science ®Google Scholar
• Balloux F, Bronstad Brynildsrud O, van Dorp L, et al. From theory to practice: translating whole-genome sequencing (WGS) into the clinic. Trends Microbiol. 2018;26(12):1035–1048.
   PubMed Web of Science ®Google Scholar
• Giordano L, Fiori B, D’Inzeo T, et al. Simplified testing method for direct detection of carbapenemase-producing organisms from positive blood cultures using the NG-test carba 5 assay. Antimicrob Agents Chemother. 2019;63(7):e00550-19.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Giani T, Di Pilato V, et al. KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues. J Antimicrob Chemother. 2019;74(8):2464–2466.
   PubMed Web of Science ®Google Scholar
• Figueroa-Espinosa R, Costa A, Cejas D, et al. MALDI-TOF MS based procedure to detect KPC-2 directly from positive blood culture bottles and colonies. J Microbiol Methods. 2019;159:120–127.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Giani T, Bassetti M, et al. Rapid microbiological tests for bloodstream infections due to multidrug resistant gram-negative bacteria: therapeutic implications. Clin Microbiol Infect. 2020;26(6):713–722.
   PubMed Web of Science ®Google Scholar
• Liotti FM, Posteraro B, Mannu F, et al. Development of a multiplex PCR platform for the rapid detection of bacteria, antibiotic resistance, and candida in human blood samples. Front Cell Infect Microbiol. 2019;9:389.
   PubMed Web of Science ®Google Scholar
• Coppi M, Di Pilato V, Monaco F, et al. Ceftazidime-avibactam resistance associated with increased bla KPC-3 gene copy number mediated by pKpQIL plasmid derivatives in sequence type 258 Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(4):e01816-19.
   PubMed Web of Science ®Google Scholar
• Findlay J, Poirel L, Juhas M, et al. KPC-mediated resistance to ceftazidime-avibactam and collateral effects in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2021;65(9):e0089021.
   PubMed Web of Science ®Google Scholar
• Sun D, Rubio-Aparicio D, Nelson K, et al. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61(12):e01694-17.
   PubMed Web of Science ®Google Scholar
• Hobson CA, Pierrat G, Tenaillon O, Bonacorsi S, Bercot B, Jaouen E, Jacquier H, Birgy A. Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0044722. doi: 10.1128/aac.00447-22. Epub 2022 Aug 18. PMID: 35980232; PMCID: PMC9487638.
   Google Scholar